PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity

dc.contributor.authorMartínez Bosch, Neus
dc.contributor.authorManero Rupérez, Noemí
dc.contributor.authorVázquez Bellón, Núria
dc.contributor.authorNickell Hernández, Bennett
dc.contributor.authorVentura Blanch, Cristina
dc.contributor.authorLutfi, Nura
dc.contributor.authorGonzález Lechuga, Carmen
dc.contributor.authorMartínez Cáceres, Carlos Manuel
dc.contributor.authorMoreno Merino, Mireia
dc.contributor.authorAmpurdanés, Coral
dc.contributor.authorAbad, Etna
dc.contributor.authorIglesias, Mar
dc.contributor.authorMuñoz Escribano, María
dc.contributor.authorJanic, Ana
dc.contributor.authorRovira, Meritxell
dc.contributor.authorGuerra, Carmen
dc.contributor.authorRabinovich, Gabriel A.
dc.contributor.authorYélamos, José
dc.contributor.authorNavarro, Pilar
dc.date.accessioned2026-07-02T14:47:00Z
dc.date.available2026-07-02T14:47:00Z
dc.date.issued2026-05-08
dc.date.updated2026-07-02T14:47:04Z
dc.description.abstractPancreatic cancer represents one of the most lethal tumors, characterized by an immunosuppressive microenvironment and a lack of cytotoxic immune cell infiltrates, which confer resistance to immunotherapy. Here, we demonstrate that deletion of poly(ADP-ribose) polymerase 2 (PARP2) in a Myc-driven mouse model of pancreatic cancer delays tumor progression and increases survival. Mechanistically, PARP2 loss induces enrichment of pathways associated with genomic instability and replicative stress, leading to increased γH2AX, chromosomal instability, and micronuclei accumulation. In addition to these tumor-intrinsic effects, PARP2 deletion reshapes the tumor microenvironment, promoting infiltration of cytotoxic T and natural killer cells while reducing immunosuppressive cell populations, enhancing antitumor cytotoxicity. These findings are recapitulated in a KrasG12D-driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease.
dc.format.extent19 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec770190
dc.identifier.pmid42102213
dc.identifier.urihttps://hdl.handle.net/2445/230395
dc.language.isoeng
dc.publisherAmerican Association for the Advancement of Science
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1126/sciadv.adu8849
dc.relation.ispartofScience Advances, 2026, vol. 12, num.19
dc.relation.urihttps://doi.org/10.1126/sciadv.adu8849
dc.rightscc-by-nc (c) Neus Martínez- Bosch et al., 2026
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceArticles publicats en revistes (Ciències Fisiològiques)
dc.subject.classificationCàncer de pàncrees
dc.subject.classificationResposta immunitària
dc.subject.otherPancreas cancer
dc.subject.otherImmune response
dc.titlePARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
937940.pdf
Mida:
4 MB
Format:
Adobe Portable Document Format